@article{GossmannFrotscherLinderetal.2016,
  author    = {Goßmann, Matthias and Frotscher, Ralf and Linder, Peter and Bayer, Robin and Epple, U. and Staat, Manfred and Temiz Artmann, Ayseg{\"u}l and Artmann, Gerhard},
  title     = {Mechano-pharmacological characterization of cardiomyocytes derived from human induced pluripotent stem cells},
  series = {Cellular physiology and biochemistry},
  volume    = {38},
  journal   = {Cellular physiology and biochemistry},
  number    = {3},
  publisher = {Karger},
  address   = {Basel},
  issn      = {1421-9778 (Online)},
  doi       = {10.1159/000443124},
  pages     = {1182 -- 1198},
  year      = {2016},
  abstract  = {Background/Aims: Common systems for the quantification of cellular contraction rely on animal-based models, complex experimental setups or indirect approaches. The herein presented CellDrum technology for testing mechanical tension of cellular monolayers and thin tissue constructs has the potential to scale-up mechanical testing towards medium-throughput analyses. Using hiPS-Cardiac Myocytes (hiPS-CMs) it represents a new perspective of drug testing and brings us closer to personalized drug medication. Methods: In the present study, monolayers of self-beating hiPS-CMs were grown on ultra-thin circular silicone membranes and deflect under the weight of the culture medium. Rhythmic contractions of the hiPS-CMs induced variations of the membrane deflection. The recorded contraction-relaxation-cycles were analyzed with respect to their amplitudes, durations, time integrals and frequencies. Besides unstimulated force and tensile stress, we investigated the effects of agonists and antagonists acting on Ca²⁺ channels (S-Bay K8644/verapamil) and Na⁺ channels (veratridine/lidocaine). Results: The measured data and simulations for pharmacologically unstimulated contraction resembled findings in native human heart tissue, while the pharmacological dose-response curves were highly accurate and consistent with reference data. Conclusion: We conclude that the combination of the CellDrum with hiPS-CMs offers a fast, facile and precise system for pharmacological, toxicological studies and offers new preclinical basic research potential.},
  language  = {en}
}
@inproceedings{HunkerJungGossmannetal.2019,
  author    = {Hunker, Jan and Jung, Alexander and Goßmann, Matthias and Linder, Peter and Staat, Manfred},
  title     = {Development of a tool to analyze the conduction speed in microelectrode array measurements of cardiac tissue},
  series = {3rd YRA MedTech Symposium 2019 : May 24 / 2019 / FH Aachen},
  booktitle = {3rd YRA MedTech Symposium 2019 : May 24 / 2019 / FH Aachen},
  editor    = {Staat, Manfred and Erni, Daniel},
  publisher = {Universit{\"a}t Duisburg-Essen},
  address   = {Duisburg},
  organization    = {MedTech Symposium},
  isbn      = {978-3-940402-22-6},
  doi       = {10.17185/duepublico/48750},
  pages     = {7 -- 8},
  year      = {2019},
  abstract  = {The discovery of human induced pluripotent stem cells reprogrammed from somatic cells [1] and their ability to differentiate into cardiomyocytes (hiPSC-CMs) has provided a robust platform for drug screening [2]. Drug screenings are essential in the development of new components, particularly for evaluating the potential of drugs to induce life-threatening pro-arrhythmias. Between 1988 and 2009, 14 drugs have been removed from the market for this reason [3]. The microelectrode array (MEA) technique is a robust tool for drug screening as it detects the field potentials (FPs) for the entire cell culture. Furthermore, the propagation of the field potential can be examined on an electrode basis. To analyze MEA measurements in detail, we have developed an open-source tool.},
  language  = {en}
}
@techreport{StoelzleFeixThomasEngelstaedteretal.2021,
  author    = {St{\"o}lzle-Feix, Sonja and Thomas, Ulrich and Engelst{\"a}dter, Max and Goßmann, Matthias and Linder, Peter and Staat, Manfred and Raman, Aravind Hariharan and Jung, Alexander and Fertig, Niels},
  title     = {Plattformtechnologie f{\"u}r kardiale Sicherheitspharmakologie basierend auf teilsynthetischem Herzmuskelgewebe (FLEXcyte) : gemeinsamer FuE-Abschlussbericht aller Partner des Verbundprojektes : Projektlaufzeit: 01.10.2018 bis 30.09.2020},
  publisher = {Nanion Technologies GmbH},
  address   = {M{\"u}nchen},
  doi       = {10.2314/KXP:1813208581},
  pages     = {IV, 85 Seiten, 2 ungez{\"a}hlte Seiten},
  year      = {2021},
  language  = {de}
}